Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
IPO Date: May 11, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $1.68B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.21 | 2.61%
Avg Daily Range (30 D): $0.43 | 2.96%
Avg Daily Range (90 D): $0.47 | 2.97%
Institutional Daily Volume
Avg Daily Volume: .76M
Avg Daily Volume (30 D): 1.85M
Avg Daily Volume (90 D): 1.81M
Trade Size
Avg Trade Size (Sh.): 79
Avg Trade Size (Sh.) (30 D): 83
Avg Trade Size (Sh.) (90 D): 83
Institutional Trades
Total Inst.Trades: 5,319
Avg Inst. Trade: $3.08M
Avg Inst. Trade (30 D): $1.77M
Avg Inst. Trade (90 D): $2.09M
Avg Inst. Trade Volume: .06M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $4.93M
Avg Closing Trade (30 D): $2.98M
Avg Closing Trade (90 D): $3.29M
Avg Closing Volume: 107.16K
   
News
Sep 8, 2025 @ 6:50 PM
BHVN Investors Have Opportunity to Lead Biohaven L...
Source: Prnewswire
Sep 7, 2025 @ 3:16 PM
Faruqi & Faruqi Reminds Biohaven Investors of the ...
Source: Faruqi & Faruqi, Llp
Sep 7, 2025 @ 2:44 PM
BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Announ...
Source: Bragar Eagel & Squire, P.C.
Sep 6, 2025 @ 2:00 PM
Pomerantz Law Firm Announces the Filing of a Class...
Source: Pomerantz Llp
Sep 5, 2025 @ 9:26 PM
Biohaven Ltd. Investors: Please contact the Portno...
Source: Portnoy Law Firm
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-1.94 $-2.17 $-1.7
Diluted EPS $-1.94 $-2.17 $-1.7
Revenue $ M $ M $ M
Gross Profit $ $ $
Net Income / Loss $ -198.15M $ -221.68M $ -160.3M
Operating Income / Loss $ -211.7M $ -221.56M $ -178.17M
Cost of Revenue $ $ $
Net Cash Flow $ 66.31M $ .15M $ -154.3M
PE Ratio